• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Ascensia partners with Snaq on diabetes management

February 21, 2023 By Sean Whooley

Ascensia Diabetes Care Contour Next One glucose meter
The Contour Next One blood glucose meter. [Image from Ascensia Diabetes Care]
Ascensia Diabetes Care announced today that it entered into a global collaboration with diabetes management company Snaq.

Snaq develops an app-based solution offering insights on food and nutrition for people with diabetes. Ascensia develops the Controu blood glucose monitoring system and distributes Senseonics’ Eversense CGM systems. The companies plan to integrate technologies to help with mealtime decisions and improve diabetes management.

Users of the Contour portfolio can integrate Snaq into their diabetes management regimen. Through the Snaq app, users can take a photo of their food and receive nutritional information and actionable insights to facilitate glycemic control. Snaq offers easy-to-read graphs and comparisons to previous meals.

The companies entered into an initial three-year collaboration. It reaches across multiple phases and regions, with a U.S. launch representing the first step. In addition to integration with Contour devices, Snaq meal data can also be shared with Ascensia’s GlucoContro.Online platform. This platform enables users to seamlessly access, analyze and share diabetes data.

“This collaboration is a further step in Ascensia’s mission to simplify diabetes management whilst providing convenient and effective solutions for people with diabetes and their healthcare providers,” said Frank Held, Ascensia head of BGM marketing and strategy. I look forward to working together with SNAQ as we collaborate to bring this valuable tool to more people.”

Snaq CEO Aurelian Briner added that the company aims to take the guesswork out of mealtime glucose control. Collaborating with Ascensia allows the company to support more people in their day-to-day choices.

“Working with Ascensia’s team is an exciting opportunity for SNAQ to grow and continue making a difference for people living with diabetes,” Briner said.

Filed Under: Business/Financial News, Diabetes, Featured, Patient Monitoring, Technology Tagged With: Ascensia Diabetes Care, Snaq

IN CASE YOU MISSED IT

  • BD’s IV catheters plant in Utah marks 70 years
  • Novo taps Nanexa for long-acting obesity injectables with €1.17B pact
  • Abbott partners with Berry Street to add nutrition coaching to Lingo
  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS